Chandrabali Ghose, Ph.D.
Founder and CEO
Chandra is passionate about finding solutions to address AMR, the silent pandemic. Prior to starting Bioharmony, Chandra was the CSO at Symbiotic Health. Chandra earned her PhD from New York University School of Medicine. Chandra did her postdoctoral research at Harvard Medical School before moving back to NYC to join Dr. David Ho's laboratory at the Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University, where she focused her research on developing vaccines. Chandra has volunteered her time at the C. Diff Foundation, NYAS NEXXT mentoring program, and at the Pew Charitable Trust’s program of “Supermoms against Superbugs” to raise awareness about antibiotic resistance, a cause she is passionate about. Chandra is a Health Innovators Fellow at the Aspen Institute.
Chris N. Garabedian.
Chairman of the Board of Directors
Chris Garabedian founded Xontogeny in 2016 to support multiple promising technologies from early development through clinical proof of concept. Most recently, Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, Chris has a broad base of experience and a track record of success across his 25 years in the pharma and biotech industries, including at two of the most successful biopharma companies over the last 20 years, Gilead and Celgene. Prior to Celgene, Chris served in a number of global leadership roles at Gilead from 1997 to 2005, including as VP of Corporate Development, VP of Medical Affairs and VP of Marketing. Chris is currently on the Board of Directors of MassBio, on the Board of Advisors for the Keck Graduate Institute and serves as a Senior Advisor for the Boston Consulting Group to their healthcare practice group.
Vincent A. Fischetti, Ph.D.
Scientific Advisory Board
Dr. Fischetti is the Head of the Laboratory of Bacterial Pathogenesis and Immunology at the Rockefeller University. Dr. Fischetti has been on the faculty of Rockefeller University since 1973. Dr. Fischetti is the leading expert and discoverer of lysins. Technology from his laboratory is currently being developed for the treatment of MRSA, Clostridium difficile and many others bacterial pathogens. He has authored more than 200 publications and holds more than 40 patents in therapeutics, devices and diagnostics space.